Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Cediranib + Olaparib for Recurrent Ovarian Cancer
Recruiting1 awardPhase 2 & 3
West Reading, Pennsylvania
This trial is testing two drugs, cediranib and olaparib, to see if they work better than standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after treatment or continued to grow during treatment.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.